Zenas BioPharma, Inc.

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb, targeting immune and inflammatory (I&I) diseases such as immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein engineered for extended half-life; and ZB001, an anti-IGF-1R monoclonal antibody. These candidates address various autoimmune and inflammatory conditions.

Zenas BioPharma is listed on the Nasdaq Global Select Market under the ticker symbol ZBIO. Its shares trade in US Dollars (USD). The company is headquartered in Waltham, Massachusetts, United States, and its stock is accessible to investors through major US brokerage platforms.

Zenas BioPharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing novel therapies for immune and inflammatory diseases, which is a core area of biotechnology. The company's pipeline includes monoclonal antibodies and fusion proteins designed to modulate the immune system.

Zenas BioPharma is headquartered in Waltham, Massachusetts, United States. The company was incorporated in 2019 and was formerly known as Zenas BioPharma (Cayman) Limited before rebranding to its current name in August 2023. Its operations are based in the US, and it focuses on developing immunology-based therapies for global markets.

Zenas BioPharma's pipeline includes several notable product candidates. Its lead candidate is obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb for autoimmune diseases like IgG4-related disease, multiple sclerosis, and lupus. Additionally, ZB002 is an anti-TNFα monoclonal antibody for inflammatory conditions. ZB004 is a CTLA-4-Ig fusion protein designed for extended half-life, and ZB001 is an anti-IGF-1R monoclonal antibody. These candidates are in various stages of clinical development.